24/7 Market News Snapshot 18 September, 2024 – Vivos Therapeutics, Inc. Common Stock (NASDAQ:VVOS)

September 18, 2024

DENVER, Colo., 18 September, 2024 (247marketnews.com) – (NASDAQ:VVOS) are discussed in this article.
Vivos Therapeutics, Inc. (NASDAQ:VVOS) is making headlines with a remarkable upward trajectory in pre-market trading, where shares surged by 32.21% to $3.702 from the previous close of $2.800. This impressive movement is underscored by substantial trading volume of 706.45K, indicating robust investor confidence and interest. The current market excitement suggests that Vivos is approaching a crucial point of growth, thus presenting an exceptional opportunity within the healthcare sector.

In an extraordinary development, Vivos has also received the first-ever FDA 510(k) clearance for its innovative oral medical device intended for the treatment of moderate to severe obstructive sleep apnea (OSA) and snoring in children aged 6 to 17. This groundbreaking approval positions Vivos at the forefront of the pediatric OSA market, addressing a pressing health concern that affects approximately 10.1 million children in the U.S. The prevalence of pediatric OSA has alarmingly increased over the last decade, with links to serious conditions like ADD/ADHD, chronic allergies, and obesity among affected children.

The company’s DNA appliance offers a non-invasive, comfortable, and effective solution, setting it apart from traditional treatment methods such as surgical interventions that often have limited success and potential for symptom relapse. In light of this landmark clearance, Vivos plans to swiftly implement its groundbreaking product into market strategies, collaborating with healthcare professionals to enhance awareness and accessibility.

Kirk Huntsman, Chairman and CEO of Vivos, emphasized the importance of this milestone, asserting that it unveils significant market opportunities while demonstrating the effectiveness of their proprietary technology. Vivos is dedicated to improving the lives of millions of children grappling with sleep-related disorders, signaling a transformative approach to pediatric healthcare.

Related news for (VVOS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.